The Checkmate-498 trial, comparing nivolumab plus radiation (RT) versus standard-of-care temozolomide plus RT in patients with newly diagnosed GBM without MGMT promoter methylation (a poor prognostic factor), was stopped after nivolumab with radiation did not show improved survival compared to temozolomide with radiation (NCT02617589, publication pending). Here, MGMT is linked to glioblastoma.